< Back to previous page
Researcher
Christophe Pannecouque
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 Jul 2002 → Today
Projects
1 - 3 of 3
- An automated platform for multiparameter data collection on live pathogens of higher or unknown biosafety risk.From26 Jun 2014 → 31 Dec 2018Funding: Hercules - Large scale research infrastructure
- Mechanistic study on virus entry and replication. A fundamental approach to the development of new and specific antiviral chemotherapeutics.From1 Jan 2010 → 31 Dec 2014Funding: BOF - Concerted Research Project from 1994
- Identification of biomarkers and new therapeutic targets in HTLV-1-associated pathologies.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project
Publications
21 - 30 of 399
- Structure-directed linker optimization of novel HEPTs as non-nucleoside inhibitors of HIV-1 reverse transcriptase(2023)
Authors: Christophe Pannecouque, Erik De Clercq
- Anti-SARS-CoV-2 Activity and Cytotoxicity of Amaryllidaceae Alkaloids from Hymenocallis littoralis(2023)
Authors: Steven De Jonghe, Johan Neyts, Christophe Pannecouque
- Development of fluorine-substituted NH2- biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability(2023)
Authors: Christophe Pannecouque, Erik De Clercq
Pages: 1192 - 1203 - From design to biological mechanism evaluation of phenylalanine-bearing HIV-1 capsid inhibitors targeting a vital assembly interface(2023)
Authors: Erik De Clercq, Christophe Pannecouque
- Hybrids of delavirdine and piperdin-4-yl-aminopyrimidines (DPAPYs) as potent HIV-1 NNRTIs: Design, synthesis and biological activities(2023)
Authors: Christophe Pannecouque
- Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors' Binding Pocket(2023)
Authors: Erik De Clercq, Christophe Pannecouque
Pages: 2102 - 2115 - Identification of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase(2023)
Authors: Erik De Clercq, Christophe Pannecouque
- Development of novel S-N3-DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity(2023)
Authors: Christophe Pannecouque, Erik De Clercq
- Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs(2023)
Authors: Christophe Pannecouque, Erik De Clercq
- Disubstituted pyrimidine-5-carboxamide derivatives as novel HIV-1 NNRTIs: Crystallographic overlay-based molecular design, synthesis, and biological evaluation(2023)
Authors: Erik De Clercq, Christophe Pannecouque
Patents
1 - 7 of 7
- Antiviral activity of bicyclic heterocycles (Inventor)
- Antiviral activity of novel bicyclic heterocycles (Inventor)
- Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- Antiviral activity of bicyclic heterocycles (Inventor)
- Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (Inventor)
- PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION (Inventor)